Anondita Medicare Sets H1 FY27 Results Meeting for 14 November
Key highlights
- Anondita Medicare scheduled its H1 FY27 results board meeting for 14 November 2026.
- The meeting agenda covers unaudited standalone and consolidated results for the half year ended 30 September 2026.
- The consolidated H2 FY26 summary reports sales of ₹83 crore, operating profit of ₹31 crore and net profit of ₹21 crore.
- The supplied FY26 annual summary reports sales of ₹137 crore and net profit of ₹34 crore.
powered by IRIS

Anondita Medicare Limited scheduled a board meeting on 14 November 2026 to consider unaudited standalone and consolidated results for the half year ended 30 September 2026, following consolidated sales of ₹83 crore and net profit of ₹21 crore reported for H2 FY26.
Know Anondita Medicare inside out
Results, valuation, peers and who's buying, in one view.
When is Anondita Medicare announcing its H1 FY27 results?
Anondita Medicare is scheduled to consider its April-September 2026 financial results at a board meeting on Saturday, 14 November 2026. The company informed the NSE that the agenda includes approval of unaudited standalone and consolidated financial results for the half year ended 30 September 2026.
The available filing describes a board-meeting agenda, not the final financial outcome. Therefore, no H1 FY27 sales, profit, margin, cash-flow or balance-sheet figures are available in the supplied information. Investors should distinguish the scheduled meeting from the eventual results announcement and board outcome filing.
The meeting falls 45 days after the end of the September half year. The prior H1 FY26 results were filed on 13 November 2025, 44 days after the relevant half-year end, according to the past-results schedule provided.
What did the company disclose to the exchange?
Anondita Medicare notified the exchange that its board would meet on 14 November 2026 to consider and approve unaudited financial results for the half year ended September 2026. The filing specifically refers to both standalone and consolidated results.
This disclosure follows the usual listed-company process in which a board considers periodic financial statements before the results are filed with the exchange. The supplied material does not state that a dividend, bonus issue, stock split, fund raising or other corporate action was on the agenda for Anondita Medicare.
For comparison, the company’s September 2025 board meeting was held on 13 November 2025. The board then approved unaudited standalone and consolidated half-yearly results, along with statements of assets and liabilities, cash flows, and a limited review report, as described in the earlier exchange outcome.
How has Anondita Medicare performed in recent half years?
The consolidated half-year figures in the supplied data show sales rising from ₹31 crore in September 2024 to ₹83 crore in March 2026. Net profit increased from ₹6 crore to ₹21 crore over the same sequence, while operating margin rose from 30.97% to 37.76%.
For H2 FY26, the consolidated summary reports sales of ₹83 crore, expenses of ₹52 crore, operating profit of ₹31 crore, profit before tax of ₹30 crore and net profit of ₹21 crore. Interest expense was ₹2 crore and depreciation was ₹1 crore in that period.
A separate detailed half-year table reports figures for March 2026 that differ from the rounded consolidated summary. It lists net sales turnover of ₹64.05 crore, total income of ₹65.05 crore and reported profit after tax of ₹15.35 crore. The supplied material does not explain the basis for the difference, so the figures should not be treated as directly comparable without the company’s underlying financial statements.
Got a follow-up? Ask IRIS
What should investors look for in the H1 FY27 filing?
Investors should look for the final reported standalone and consolidated revenue, operating profit, net profit and margin figures for the half year ended 30 September 2026. Comparison with the September 2025 results can help show whether the recent increase in sales and profitability has continued.
The detailed financial statements, if filed, may also provide statements of assets and liabilities and cash flows, consistent with the documents submitted with the September 2025 results. These disclosures can add context on working capital, borrowings, interest cost and operating cash generation beyond the profit and loss account.
The historical figures show higher operating profit and margin through the periods presented, but the scheduled board meeting itself does not establish an H1 FY27 trend. Any assessment of current performance should wait for the approved results and accompanying review report.
Why does the results schedule matter for the market?
The results schedule matters because it sets the expected point at which investors receive updated financial information for Anondita Medicare. Periodic results can affect how investors assess revenue growth, profitability and the pace of business activity, particularly when prior reported half-year performance has improved.
The company’s annual figures in the supplied data show sales of ₹137 crore in March 2026, compared with ₹77 crore in March 2025. Annual net profit was reported at ₹34 crore, compared with ₹16 crore a year earlier, while operating margin increased to 37.23% from 33.36%.
However, these historical numbers are not a forecast for H1 FY27. The immediate market-relevant development is the results review scheduled for 14 November, with the final exchange filing needed to confirm the financial outcome.
Conclusion
Anondita Medicare has scheduled consideration of its unaudited standalone and consolidated H1 FY27 results for 14 November 2026. Historical information supplied for earlier periods indicates growth in reported sales, operating profit and net profit, although the two March 2026 half-year data presentations use different figures and cannot be reconciled from the available material.
The next item to watch is the company’s board outcome and financial-results filing for the half year ended 30 September 2026. That disclosure should confirm the final reported numbers, the review documentation and any information that the board formally approves beyond the stated results agenda.


